Asset Value Investors Ltd., a UK‑based activist fund, has formally urged the board of Rohto Pharmaceutical Co. to remove its chairman immediately. The demand appears in a filing that adds Rohto to a growing list of Japanese companies confronting shareholder pressure this year. AVI argues the current leadership hinders value creation for investors and may jeopardize its long‑term strategic plan.

Rohto, known for over‑the‑counter remedies and consumer health products, has seen its share price stagnate despite a robust domestic market. AVI’s campaign suggests the board has missed opportunities to streamline operations or pursue overseas acquisitions that could boost earnings. By targeting the chairman, the fund signals a willingness to reshape governance if shareholders are not heard in the near term.

Investors will watch how Rohto’s directors respond, as a forced resignation could trigger a proxy battle and reshape the company’s strategic direction. Should AVI succeed, the move may encourage other activist groups to challenge Japanese boards, potentially accelerating governance reforms across the sector. The immediate outcome will hinge on the board’s next public statement in the coming week for clarity.